{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:48:37Z","timestamp":1775566117143,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucosylsphingosine (Lyso-GL-1), a glycosphingolipid formed by glucosylceramide hydrolysis, is known to be increased in Gaucher disease. Recently, increased ceramides and sphingolipids have been implicated in obesity, insulin resistance, and atherogenesis. However, limited data exists on serum Lyso-GL-1 level in children with obesity and its relation with insulin resistance, lipid dysfunction, and atherogenesis. Hence, this study aimed to assess Lyso-GL-1 level among children with obesity and correlate it with biomarkers of insulin resistance and atherogenic index of plasma (AIP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Sixty children with obesity with a mean age of 10.06 years (SDS\u2009\u00b1\u20092.22) and 60 age- and sex-matched normal-weighed controls were assessed for anthropometric measures, mean blood pressure percentiles, serum Lyso-GL-1, glycated hemoglobin (HbA1c), fasting insulin, triglycerides, cholesterol, low-density (LDL-C) and high-density lipoprotein cholesterol (HDL-C) with calculation of the homeostatic model assessment of insulin resistance (HOMA-IR) and the AIP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Children with obesity have significantly higher Lyso-GL-1 and AIP than controls. Lyso-GL-1 is significantly positively correlated with body mass index (BMI) z-score, waist\/hip ratio z-score, systolic and diastolic blood pressure percentiles, LDL-C, HOMA-IR, and AIP (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), being independently correlated with systolic blood pressure percentile, LDL-C, and AIP on multivariate regression analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum Lyso-GL-1 is elevated in children with obesity, being closely correlated with hypertension, insulin resistance, and atherogenesis. This could provide a mechanistic insight on the role of Lyso-GL-1 in obesity and atherogenesis. Further studies are warranted to explore the potential role of Lyso-GL-1 as a biomarker and target for the prevention and treatment of obesity-related atherogenesis and insulin resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41366-025-02016-9","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:58:32Z","timestamp":1769054312000},"page":"861-868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated serum glucosylsphingosine level in children with obesity: relation to plasma atherogenesis"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-8835","authenticated-orcid":false,"given":"Nouran Y.","family":"Salah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Abdel Hakam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma AbdEllah","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa Samir","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Aly","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2016_CR1","first-page":"1157","volume":"1864","author":"M Rakhshandehroo","year":"2019","unstructured":"Rakhshandehroo M, Van Eijkeren RJ, Gabriel TL, de Haar C, Gijzel SMW, Hamers N, et al. Adipocytes harbor a glucosylceramide biosynthesis pathway involved in iNKT cell activation. Biochim Biophys Acta (BBA) Mol Cell Biol Lipids. 2019;1864:1157\u201367.","journal-title":"Biochim Biophys Acta (BBA) Mol Cell Biol Lipids"},{"key":"2016_CR2","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","volume":"37","author":"YV Taguchi","year":"2017","unstructured":"Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, et al. Glucosylsphingosine promotes \u03b1-synuclein pathology in mutant GBA-associated Parkinson\u2019s disease. J Neurosci. 2017;37:9617\u201331.","journal-title":"J Neurosci"},{"key":"2016_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.24491","volume":"91","author":"V Murugesan","year":"2016","unstructured":"Murugesan V, Chuang W, Liu J, Lischuk A, Kacena K, Lin H, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91:1082\u20139.","journal-title":"Am J Hematol"},{"key":"2016_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2337\/db06-1619","volume":"56","author":"JM Aerts","year":"2007","unstructured":"Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, et al. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes. 2007;56:1341\u20139.","journal-title":"Diabetes"},{"key":"2016_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-physiol-031620-093815","volume":"83","author":"B Chaurasia","year":"2020","unstructured":"Chaurasia B, Summers SA. Ceramides in metabolism: key lipotoxic players. Annu Rev Physiol. 2020;83:303\u201330.","journal-title":"Annu Rev Physiol"},{"key":"2016_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.plipres.2009.03.002","volume":"48","author":"M Langeveld","year":"2009","unstructured":"Langeveld M, Aerts JMFG. Glycosphingolipids and insulin resistance. Prog Lipid Res. 2009;48:196.","journal-title":"Prog Lipid Res"},{"key":"2016_CR7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cmet.2021.06.006","volume":"33","author":"CD Green","year":"2021","unstructured":"Green CD, Maceyka M, Cowart LA, Spiegel S. Sphingolipids in metabolic disease: The good, the bad, and the unknown. Cell Metab. 2021;33:1293\u2013306.","journal-title":"Cell Metab"},{"key":"2016_CR8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/ajcn\/nqz257","volume":"111","author":"ME Walker","year":"2020","unstructured":"Walker ME, Xanthakis V, Moore LL, Vasan RS, Jacques PF. Cumulative sugar-sweetened beverage consumption is associated with higher concentrations of circulating ceramides in the Framingham Offspring Cohort. Am J Clin Nutr. 2020;111:420\u20138.","journal-title":"Am J Clin Nutr"},{"key":"2016_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.15698\/cst2025.07.308","volume":"9","author":"V Schmiedhofer","year":"2025","unstructured":"Schmiedhofer V, Sommersguter-Wagner J, Knittelfelder O, Jungwirth H, Rechberger G, Carmona-Gutierrez D, et al. Sugar accelerates chronological aging in yeast via ceramides. Cell Stress. 2025;9:158\u201373.","journal-title":"Cell Stress"},{"key":"2016_CR10","doi-asserted-by":"publisher","unstructured":"Giuffrida G, Markovic U, Condorelli A, Calafiore V, Nicolosi D, Calagna M, et al. Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review. Orphanet J Rare Dis. 2023;18. https:\/\/doi.org\/10.1186\/s13023-023-02623-7.","DOI":"10.1186\/s13023-023-02623-7"},{"key":"2016_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41574-020-0320-5","volume":"16","author":"SM Turpin-Nolan","year":"2020","unstructured":"Turpin-Nolan SM, Br\u00fcning JC. The role of ceramides in metabolic disorders: when size and localization matters. Nat Rev Endocrinol. 2020;16:224\u201333.","journal-title":"Nat Rev Endocrinol"},{"key":"2016_CR12","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Ruiz I Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling. Nature Reviews Cardiology. 2025. https:\/\/doi.org\/10.1038\/s41569-025-01149-8.","DOI":"10.1038\/s41569-025-01149-8"},{"key":"2016_CR13","doi-asserted-by":"publisher","unstructured":"Jin K, Ma Z, Zhao C, Zhou X, Xu H, Li D, et al. The correlation between the atherogenic index of plasma and the severity of coronary artery disease in acute myocardial infarction patients under different glucose metabolic states. Sci Rep. 2025;15. https:\/\/doi.org\/10.1038\/s41598-025-90816-4.","DOI":"10.1038\/s41598-025-90816-4"},{"key":"2016_CR14","doi-asserted-by":"publisher","unstructured":"Ali T, Helal R, Khaled R, Sabbour H, Lessan N. Atherogenic index of plasma associated cardiovascular risk in 10,241 pediatric patients. Endocrine Abstracts. 2023. https:\/\/doi.org\/10.1530\/endoabs.90.ep374.","DOI":"10.1530\/endoabs.90.ep374"},{"key":"2016_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fped.2020.00368","volume":"8","author":"A El Shafie","year":"2020","unstructured":"El Shafie A, El-Gendy F, Allahony D, Omar Z, Samir M, El-Bazzar A, et al. Establishment of Z-score reference of growth parameters for Egyptian school children and adolescents aged from 5 to 19 years: a cross-sectional study. Front Pediatr. 2020;8:368.","journal-title":"Front Pediatr"},{"key":"2016_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(10)61134-8","volume":"376","author":"A Saint-Raymond","year":"2010","unstructured":"Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, Bero L. CONSORT 2010. Lancet. 2010;376:229\u201330.","journal-title":"Lancet"},{"key":"2016_CR17","doi-asserted-by":"publisher","first-page":"962","DOI":"10.26719\/2012.18.9.962","volume":"18","author":"A El-Gilany","year":"2012","unstructured":"El-Gilany A, El-Wehady A, El-Wasify M. Updating and validation of the socioeconomic status scale for health research in Egypt. East Mediterranean Health J. 2012;18:962\u20138.","journal-title":"East Mediterranean Health J"},{"key":"2016_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12519-008-0048-0","volume":"4","author":"P Schwandt","year":"2008","unstructured":"Schwandt P, Kelishadi R, Haas GM. First reference curves of waist circumference for German children in comparison to international values: the PEP Family Heart Study. World J Pediatr. 2008;4:259\u201366.","journal-title":"World J Pediatr"},{"key":"2016_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.endonu.2012.12.003","volume":"60","author":"M Mederico","year":"2013","unstructured":"Mederico M, Paoli M, Zerpa Y, Brice\u00f1o Y, G\u00f3mez-P\u00e9rez R, Mart\u00ednez JL, et al. Grupo de trabajo CREDEFAR. Reference values of waist circumference and waist\/hip ratio in children and adolescents of M\u00e9rida, Venezuela: comparison with international references. Endocrinol\u00eda Y Nutrici\u00f3n (Engl Ed). 2013;60:235\u201342.","journal-title":"Endocrinol\u00eda Y Nutrici\u00f3n (Engl Ed)"},{"key":"2016_CR20","doi-asserted-by":"publisher","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll A, Danielset S, et al. Subcommittee on screening and management of high blood pressure in children. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. PEDIATRICS. 2017;140. https:\/\/doi.org\/10.1542\/peds.2017-1904.","DOI":"10.1542\/peds.2017-1904"},{"key":"2016_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/adc.44.235.291","volume":"44","author":"WA Marshall","year":"1969","unstructured":"Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291\u2013303.","journal-title":"Arch Dis Child"},{"key":"2016_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1157\/13102513","volume":"66","author":"BG Cuartero","year":"2007","unstructured":"Cuartero BG, Lacalle CG, Lobo CJ, Vergaz AG, Rey C, Villar MJ, et al. \u00cdndice HOMA y QUICKI, insulina y p\u00e9ptido C en ni\u00f1os sanos. Puntos de corte de riesgo cardiovascular. An De Pediatr\u00eda. 2007;66:481\u201390.","journal-title":"An De Pediatr\u00eda"},{"key":"2016_CR23","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.106.620864","volume":"114","author":"CJ Jolliffe","year":"2006","unstructured":"Jolliffe CJ, Janssen I. Distribution of lipoproteins by age and gender in adolescents. Circulation. 2006;114:1056\u201362.","journal-title":"Circulation"},{"key":"2016_CR24","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","volume":"128","author":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute.","year":"2011","unstructured":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128:S213\u201356.","journal-title":"Pediatrics"},{"key":"2016_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/children10040641","volume":"10","author":"H Da\u011f","year":"2023","unstructured":"Da\u011f H, \u0130ncirku\u015f F, Dikker O. Atherogenic index of plasma (AIP) and its association with fatty liver in obese adolescents. Children. 2023;10:641.","journal-title":"Children"},{"key":"2016_CR26","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1161\/01.CIR.0000088846.10655.E0","volume":"108","author":"MP Reilly","year":"2003","unstructured":"Reilly MP, Rader DJ. The metabolic syndrome. Circulation. 2003;108:1546\u201351.","journal-title":"Circulation"},{"key":"2016_CR27","doi-asserted-by":"publisher","unstructured":"Hammerschmidt P, Br\u00fcning JC Contribution of specific ceramides to obesity-associated metabolic diseases. Cell Mol Life Sci. 2022;79. https:\/\/doi.org\/10.1007\/s00018-022-04401-3.","DOI":"10.1007\/s00018-022-04401-3"},{"key":"2016_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2017.08.005","volume":"122","author":"D Elstein","year":"2017","unstructured":"Elstein D, Mellgard B, Dinh Q, Lan L, Qiu Y, Cozma C, et al. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-na\u00efve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: data from phase 3 clinical trials. Mol Genet Metab. 2017;122:113\u201320.","journal-title":"Mol Genet Metab"},{"key":"2016_CR29","doi-asserted-by":"publisher","unstructured":"Mameli C, Carnovale C, Ambrogi F, Infante G, Biejat PR, Napoli A, et al. Increased acid sphingomyelinase levels in pediatric patients with obesity. Sci Rep. 2022:10996. https:\/\/doi.org\/10.1038\/s41598-022-14687-9.","DOI":"10.1038\/s41598-022-14687-9"},{"key":"2016_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1210\/er.2007-0025","volume":"29","author":"WL Holland","year":"2008","unstructured":"Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008;29:381\u2013402. https:\/\/doi.org\/10.1210\/er.2007-0025.","journal-title":"Endocr Rev"},{"key":"2016_CR31","doi-asserted-by":"publisher","unstructured":"Samad F, Badeanlou L, Shah C, Yang G. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. Adv Exp Med Biol. 2011:67\u201386. https:\/\/doi.org\/10.1007\/978-1-4614-0650-1_5.","DOI":"10.1007\/978-1-4614-0650-1_5"},{"key":"2016_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.plipres.2009.03.002","volume":"48","author":"M Langeveld","year":"2009","unstructured":"Langeveld M, Aerts JMFG. Glycosphingolipids and insulin resistance. Prog Lipid Res. 2009;48:196\u2013205.","journal-title":"Prog Lipid Res"},{"key":"2016_CR33","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2337\/db06-0719","volume":"56","author":"H Zhao","year":"2007","unstructured":"Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes. 2007;56:1210\u20138.","journal-title":"Diabetes"},{"key":"2016_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0022-2275(20)36996-0","volume":"17","author":"G Dawson","year":"1976","unstructured":"Dawson G, Kruski AW, Scanu AM. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976;17:125\u201331.","journal-title":"J Lipid Res"},{"key":"2016_CR35","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/atvbaha.116.305675","volume":"36","author":"A Edsfeldt","year":"2016","unstructured":"Edsfeldt A, Dun\u00e9r P, St\u00e5hlman M, Mollet I, Ascuitto G, Grufman H, et al. Sphingolipids contribute to human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol. 2016;36:1132\u201340. https:\/\/doi.org\/10.1161\/atvbaha.116.305675.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2016_CR36","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.3390\/nu16193296","volume":"16","author":"D Foran","year":"2024","unstructured":"Foran D, Antoniades C, Akoumianakis I. Emerging roles for sphingolipids in cardiometabolic disease: a rational therapeutic target?. Nutrients. 2024;16:3296.","journal-title":"Nutrients"},{"key":"2016_CR37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1161\/ATVBAHA.109.201673","volume":"30","author":"F Bietrix","year":"2010","unstructured":"Bietrix F, Lombardo E, Van Roomen CPAA, Ottenhof R, Vos M, Rensen P, et al. Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor\u2212\/\u2212 mice. Arterioscler Thromb Vasc Biol. 2010;30:931\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2016_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2012.08.041","volume":"226","author":"T Hornemann","year":"2012","unstructured":"Hornemann T, Worgall TS. Sphingolipids and atherosclerosis. Atherosclerosis. 2012;226:16\u201328.","journal-title":"Atherosclerosis"},{"key":"2016_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.cmet.2012.06.017","volume":"16","author":"T Hla","year":"2012","unstructured":"Hla T, Dannenberg AJ. Sphingolipid signaling in metabolic disorders. Cell Metab. 2012;16:420\u201334.","journal-title":"Cell Metab"},{"key":"2016_CR40","doi-asserted-by":"publisher","unstructured":"Borodzicz S, Czarzasta K, Kuch M, Cudnoch-Jedrzejewska A. Sphingolipids in cardiovascular diseases and metabolic disorders. Lipids Health Dis. 2015;14. https:\/\/doi.org\/10.1186\/s12944-015-0053-y.","DOI":"10.1186\/s12944-015-0053-y"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-02016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-02016-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-02016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:56:40Z","timestamp":1775563000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-02016-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1038\/s41366-025-02016-9","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"24 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Ethical Committee of Ain Shams University with an approval number R 200\/2021, and written informed consent was obtained from all cases and their legal guardians before participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}